Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2008 February;56(1) > Minerva Cardioangiologica 2008 February;56(1):155-66





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2008 February;56(1):155-66

language: English

Future stent drug delivery systems

Caixeta A. 1, Abizaid A. 2,3, Aoki J. 2,3, Dangas G. 2,3, Mehran R. 2,3

1 Heart Institute, Brasilia, DF, Brazil
2 Columbia University Medical Center New York, NY, USA
3 Cardiovascular Research Foundation New York, NY, USA


Drug-eluting stents (DES) with antiproliferative drugs attached via polymers on the stent surface have reduced in-stent restenosis and repeat revascularization compared with bare metal stent (BMS) across nearly all lesion and patient subsets. However, the small number of patients with in-stent restenosis after DES treatment still exists. Furthermore, concerns about long-term safety of DES are raised, particularly regarding the higher-than-expected late-event thrombosis. There is no doubt that the DES will continue to play a pivotal role in the treatment of coronary artery disease, yet future designs need to incorporate features that reduce thrombosis and promote endothelialization along with maintaining the efficacy. This review focuses on novel generation of DES, discussing new programs, including new antiproliferative agents, novel polymeric and non polymeric stents.

top of page

Publication History

Cite this article as

Corresponding author e-mail